Home › Colorectal Cancer › Wisconsin › Madison
Pag-aaral pangklinika para sa Colorectal Cancer sa Madison, WI
Isang pag-aaral para sa Colorectal Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Madison. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Nagre-recruitPhase 2
- University of Wisconsin, Madison
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- University of Wisconsin Carbone Cancer Center, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Nagre-recruitPhase 2
- UW Health Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Nagre-recruitPhase 1
- Wisconsin Institute for Medical Research, Madison
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Nagre-recruitPhase 1/2
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Nagre-recruitPhase 1/2
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293), Madison
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Nagre-recruitPhase 3
- William S. Middleton Memorial VA, Madison
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Nagre-recruitPhase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Nagre-recruitPhase 2
- Research Site, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Nagre-recruitPhase 1
- University of Wisconsin - Carbone Cancer Center, Madison
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Nagre-recruitPhase 2
- University of Wisconsin Carbone Cancer Center, Madison
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
Nagre-recruitPhase 2
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Nagre-recruitPhase 3
- Clinical Study Site, Madison
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
Nagre-recruitPhase 1
- Univ of Wisconsin-Madison, Madison
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Nagre-recruitPhase 1
- University of Wisconsin - Carbone Cancer Center, Madison
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- University of Wisconsin, Carbone Cancer Center, Madison
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- University of Wisconsin- Madison, Madison
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Nagre-recruitPhase 1/2
- GSK Investigational Site, Madison
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Nagre-recruitPhase 1/2
- University of Wisconsin, Madison
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Nagre-recruitPhase 1
- University of Wisconsin (Carbone Cancer Center), Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Nagre-recruitObservasyonal na pag-aaral
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Nagre-recruitPhase 4
- University of Wisconsin, Madison
Pag-aaral para sa Colorectal Cancer sa ibang lungsod
- Houston, TX102 pag-aaral
- New York City, NY78 pag-aaral
- Nashville, TN69 pag-aaral
- Boston, MA63 pag-aaral
- Los Angeles, CA59 pag-aaral
- Arlington, VA52 pag-aaral
- St. Louis, MO50 pag-aaral
- San Antonio, TX46 pag-aaral
- Philadelphia, PA44 pag-aaral
- Grand Rapids, MI40 pag-aaral
- Baldwin Park, CA37 pag-aaral
- Chicago, IL34 pag-aaral
Iba pang pag-aaral sa Madison
- Kanser sa Prostate29 pag-aaral
- Kanser sa Suso22 pag-aaral
- Metastatic Cancer21 pag-aaral
- Acute Myeloid Leukemia16 pag-aaral
- Non-Small Cell Lung Cancer16 pag-aaral
- Melanoma15 pag-aaral
- Kanser (lahat ng uri)14 pag-aaral
- Kanser sa Ovary13 pag-aaral
- Kanser sa Tiyan11 pag-aaral
- Kanser sa Pancreas10 pag-aaral
- Kanser sa Baga10 pag-aaral
- Multiple Myeloma9 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.